I suddenly had this vision - Leronlimab could get EUA now from FDA for mild only; this would synch up with FDA granting moderate EAU yesterday to Remdesivir. And in that scenario, either (1) we would be told by FDA to do a small P3 for moderate only or (2) we would be told by FDA that if our interim analysis looks good for P3 severe/critical, then they might be inclined to grant EAU for moderate/severe/critical at that time (ie mid October).